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Abstract
Background: Phosphatidylinositol 4,5-bisphosphate (PIP2) is required for successful completion
of cytokinesis. In addition, both PIP2 and phosphoinositide-specific phospholipase C (PLC) have
been localized to the cleavage furrow of dividing mammalian cells. PLC hydrolyzes PIP2 to yield
diacylglycerol (DAG) and inositol trisphosphate (IP3), which in turn induces calcium (Ca2+) release
from the ER. Several studies suggest PIP2 must be hydrolyzed continuously for continued cleavage
furrow ingression. The majority of these studies employ the N-substituted maleimide U73122 as
an inhibitor of PLC. However, the specificity of U73122 is unclear, as its active group closely
resembles the non-specific alkylating agent N-ethylmaleimide (NEM). In addition, the pathway by
which PIP2 regulates cytokinesis remains to be elucidated.
Results: Here we compared the effects of U73122 and the structurally unrelated PLC inhibitor
ET-18-OCH3 (edelfosine) on cytokinesis in crane-fly and Drosophila spermatocytes. Our data show
that the effects of U73122 are indeed via PLC because U73122 and ET-18-OCH3 produced similar
effects on cell morphology and actin cytoskeleton organization that were distinct from those
caused by NEM. Furthermore, treatment with the myosin light chain kinase (MLCK) inhibitor ML-
7 caused cleavage furrow regression and loss of both F-actin and phosphorylated myosin regulatory
light chain from the contractile ring in a manner similar to treatment with U73122 and ET-18-
OCH3.
Conclusion: We have used multiple inhibitors to examine the roles of PLC and MLCK, a predicted
downstream target of PLC regulation, in cytokinesis. Our results are consistent with a model in
which PIP2 hydrolysis acts via Ca2+ to activate myosin via MLCK and thereby control actin dynamics
during constriction of the contractile ring.
Background
Cell proliferation and growth require the coordination of
cell signaling pathways. PLC plays an important role in
cell signaling, mediating transduction of signals from a
variety of intracellular and extracellular stimuli [1,2]. PLC-
dependent hydrolysis of PIP2 produces the second mes-
sengers DAG and IP3 (reviewed in [3]). IP3 binds specific
receptors on the ER to mobilize calcium (Ca2+) from inter-
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nal stores. DAG and Ca2+ activate protein kinase C (PKC),
which stimulates cell growth [4]. In addition, Ca2+ itself
facilitates diverse cellular events including membrane
trafficking, contractility and proliferation [5]. PLC-
dependent pathways thus play key roles in promoting cell
growth.
The synthetic aminosteroid U73122 (Figure 1A) is an
important tool in identifying and studying PLC-depend-
ent processes. Initially discovered in a search for inhibi-
tors of platelet activation, U73122 was found to inhibit
PLC function [6]. U73122 causes decreases in IP3 and
DAG production, calcium levels, and phosphatidylinosi-
tol (PI) turnover in agonist-stimulated platelets, indicat-
ing that U73122 blocks PLC-mediated hydrolysis of PIP2
in treated cells [7]. The mechanism of action of U73122 is
currently unknown [8], although an examination of its
structure can provide some insight into the biologically
active domains of the molecule. The inhibitory activity of
U73122 can be reduced by alteration of the C17 side
chain or removal of the 3-methoxy group [7]. Substitution
of the electrophilic maleimide group of U73122 with the
less electrophilic succinimide produces the inactive iso-
mer U73343, which differs from the active form only by
the absence of a double bond on the pyrrole ring (Figure
1B). Thus, reactivity appears to reside largely in the NEM
moiety of the molecule. NEM (Figure 1C) is a sulfhydryl
alkylating agent that covalently modifies cysteine resi-
dues, raising the possibility that U73122 acts by a similar
mechanism.
Using inhibitors affecting PI metabolism, we previously
showed that continuous PI cycling is required for cytoki-
nesis [9]. In particular, treatment of cells with U73122
resulted in regression of the cleavage furrow and failure of
cytokinesis [9,10]. The effects of U73122 suggested PIP2
hydrolysis is required for normal cytokinesis. Indeed,
cytokinesis failed in cells treated with an IP3 receptor
antagonist or in which intracellular Ca2+ was chelated by
BAPTA-AM [10]. Perhaps most strikingly, our data indi-
cated that PIP2 hydrolysis may be required to maintain F-
actin in the contractile ring [9].
U73122 may exert non-specific effects, however, because
several lines of evidence suggest that U73122 may affect
phosphoinositide cycling or Ca2+ levels independent of
PLC inhibition. In rabbit platelets, U73122 caused up to
50% reduction in the levels of phosphatidylinositol 4-
phosphate (PIP) and PIP2, but not PI, indicating that
U73122 may inhibit both PI and PIP kinases. Although
IP3 levels were reduced in agonist-stimulated cells, con-
sistent with inhibition of PLC, this may have been an indi-
rect effect of a shortage in substrate availability [11]. In
U73122-treated mouse fibroblasts and rat neutrophils,
inhibition of Ca2+ influx across the plasma membrane
contributed to the suppression of Ca2+ levels [12,13]. In
contrast, U73122 actually increased Ca2+ release from
internal stores in rat pancreatic acinar cells and rat liver
microsomes [14,15].
A second PLC inhibitor, the lysophosphatidylcholine ana-
logue ET-18-OCH3 (Figure 1D; [16]), is of interest in can-
cer therapy because of its demonstrated anti-tumor
properties [17]. ET-18-OCH3  and related compounds
inhibit phosphatidylinositol 3-kinases and PKC [18-21]
and selectively promote tumor cell apoptosis [17,22]. Like
U73122, ET-18-OCH3 also has other off-target effects,
including release of Ca2+ from intracellular stores [23].
However, unlike U73122, ET-18-OCH3 is inserted in the
plasma membrane, and its effects may be due in part to
alteration of membrane lipid and protein composition
[24-26]. In both human histiocytic lymphoma and tum-
origenic rat liver cells, ET-18-OCH3 inhibits cytokinesis
[27,28].
To determine if U73122 inhibits cytokinesis via PLC, we
compared the effects of U73122 with those of ET-18-
OCH3 and NEM. We further examined the role of a poten-
tial downstream target of PLC activity, MLCK. We found
that inhibition of MLCK perturbed cytokinesis in a man-
ner similar to inhibition of PLC by U73122 and ET-18-
OCH3. Our results are consistent with a model in which
PLC and MLCK act in the same pathway to maintain the
integrity of the contractile ring, implicating MLCK as a tar-
get of Ca2+ regulation in this process.
Results
PLC inhibition causes cleavage furrows to regress
We previously showed that the PLC inhibitor U73122
caused cleavage furrow regression during cytokinesis in
crane-fly and Drosophila melanogaster spermatocytes
[9,10]. In control cells, cytokinesis was initiated by invagi-
nation of the equatorial plasma membrane to form a fur-
Chemical structures of PLC inhibitors and controls Figure 1
Chemical structures of PLC inhibitors and controls. 
Chemical structures of (A) U73122, (B) U73343, (C) NEM 
and (D) ET-18-OCH3.BMC Cell Biology 2007, 8:15 http://www.biomedcentral.com/1471-2121/8/15
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row between the nascent daughter cells (Figure 2A, B) [see
Additional files 1, 2] [10,29]. Ingression continued una-
bated until the cleavage furrow reached a minimum diam-
eter of one to several micrometers (Figure 2E). When
added after initiation of furrowing, U73122 arrested cyto-
kinesis and caused cleavage furrow regression (Figure 2C,
D, F) [see Additional files 3, 4] [9,10]. During cleavage,
mitochondria and parafusorial membranes along the
spindle become constricted as the plasma membrane
ingressed at the equator [10]. In Drosophila spermatocytes
treated with U73122, these structures remained con-
stricted as the plasma membrane regressed, and often
underwent continued constriction of several micrometres
after regression of the furrow (Figure 2D). The effects of
U73122 were not reversible at any concentration in Dro-
sophila; however, in crane-fly spermatocytes, the effects at
the minimum effective dosage of U73122 were reversed
after washing [9].
To determine if a second PLC inhibitor had a similar
effect, we treated dividing crane-fly and Drosophila sper-
matocytes with ET-18-OCH3. In both species, ET-18-
OCH3 inhibited cytokinesis and caused the cleavage fur-
row to regress (Figure 3A, B, C) [see Additional files 5, 6].
These effects were seen at concentrations of 30 µM or
greater in Drosophila spermatocytes (Figure 3D) and 35
µM or greater in crane-fly spermatocytes (data not
shown). In crane-fly spermatocytes, but not in Drosophila
spermatocytes, cleavage furrow regression was reversible
in 2/4 treated cells. Thus U73122 and ET-18-OCH3 have
similar effects on cytokinesis.
Alkylation stops furrow ingression but does not cause 
regression
To determine if the effects of U73122 were due to non-
specific alkylation of off-target proteins, we directly exam-
ined the effects of the alkylating agent NEM on cytokine-
sis. In both crane-fly and Drosophila spermatocytes, NEM
stopped cytokinesis but did not cause regression of the
cleavage furrow (Figure 4A, B) [see Additional files 7, 8].
ET-18-OCH3 causes cleavage furrow regression in crane-fly  and Drosophila spermatocytes Figure 3
ET-18-OCH3 causes cleavage furrow regression in 
crane-fly and Drosophila spermatocytes. (A, B) Time-
lapse phase-contrast micrographs showing ET-18-OCH3-
treated dividing (A) crane-fly or (B) Drosophila spermatocytes 
[see Additional files 5, 6]. For each cell, 35 µM ET-18-OCH3 
was added just after the time-point depicted in the second 
panel. Bars, 10 µm. (C) Plot of the change in cell diameter 
(ordinate) over time (abscissa) for the crane-fly (+) and Dro-
sophila (o) spermatocytes shown in A, B. Arrows indicate 
time of drug addition. (D). Sensitivity of Drosophila spermato-
cyte cytokinesis to increasing concentrations of ET-18-
OCH3. Cytokinesis failed in the majority of cells treated with 
30 µM and in all cells treated with 35–40 µM ET-18-OCH3.
U73122 causes cleavage furrow regression in crane-fly and  Drosophila spermatocytes Figure 2
U73122 causes cleavage furrow regression in crane-
fly and Drosophila spermatocytes. (A, B) Phase-contrast 
images showing time-course of cytokinesis in untreated (A) 
crane-fly and (B) Drosophila spermatocytes [see Additional 
files 1, 2]. Times are in min:sec. Bars, 10 µm. (C, D) Phase-
contrast time-course of a (C) crane-fly and (D) Drosophila 
spermatocyte treated with U73122 during cytokinesis [see 
Additional files 3, 4]. U73122 was added immediately after 
the time-point depicted in the second panel. Crane-fly and 
Drosophila spermatocytes were treated with 4.3 µM and 10 
µM U73122 respectively. Note that the crane-fly spermato-
cyte was followed for only a short time after treatment (for a 
longer time-course, see [9]). Bars, 10 µm. (E) Plot of the 
change in cell diameter (ordinate) over time (abscissa) for 
the treated crane-fly (+) and Drosophila (o) spermatocytes 
shown in A, B. (F) Plot of the change in cell diameter (ordi-
nate) over time (abscissa) for the crane-fly (+) and Drosophila 
(o) spermatocytes shown in C, D. Arrows indicate time of 
drug treatment.BMC Cell Biology 2007, 8:15 http://www.biomedcentral.com/1471-2121/8/15
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The effective concentration differed between the two spe-
cies. In crane-fly spermatocytes, NEM inhibited furrowing
at concentrations of 50 µM or greater. Cleavage arrest
occurred immediately after treatment and cleavage fur-
rows did not regress or resume constriction even after the
drug was washed out (Figure 4C). In Drosophila spermato-
cytes, NEM also irreversibly stopped furrowing, although
it was effective at concentrations as low as 500 nM (Figure
4B, C). In addition, NEM caused large blebs to form on
the plasma membrane (Figure 4B, arrowheads) [see Addi-
tional file 8]. NEM did not cause regression of cleavage
furrows at any concentration tested (up to 100 µM).
Myosin Light Chain Kinase (MLCK) inactivation causes 
cleavage furrows to regress
To test if IP3  receptor-mediated Ca2+  release activates
MLCK during cytokinesis [10], we examined the effects of
ML-7, an inhibitor of MLCK and hence of myosin activa-
tion. A concentration range of 75–80 µM was chosen
because lower concentrations had little or no effect on
cytokinesis ([29]; not shown). In both crane-fly and Dro-
sophila spermatocytes, treatment with 75 µM (crane-fly) or
80 µM (Drosophila) ML-7 caused cleavage furrow regres-
sion ([29]; Figure 5A) [see Additional file 9]. Treatment of
Drosophila spermatocytes with ML-7 was reversible upon
washout (Figure 5B) [see Additional file 9], unlike treat-
ment with U73122, ET-18-OCH3 or NEM; however, after
resuming, ingression arrested prematurely in 21 out of 33
cells. Thus, the effects of ML-7 on cytokinesis in Drosophila
spermatocytes are identical to those previously reported
in crane-fly spermatocytes [29]. That ML-7 treatment
blocks cytokinesis in a manner similar to U73122 and ET-
18-OCH3 is consistent with PLC and MLCK acting in the
same pathway.
PLC and MLCK activities are required to maintain actin at 
the cleavage furrow
To investigate the effect of the various inhibitors on
cytoskeletal components, we stained crane-fly spermato-
cytes for F-actin and tubulin. In control cells, actin fila-
ments were arranged in a circumferential band around the
equator of the cell, with very little F-actin at the poles.
Tubulin was present in spindle and astral microtubules
and was organized longitudinally from pole-to-pole (Fig-
ure 6A, A'). After treatment with U73122, tubulin organi-
zation was similar to that of control cells. However, actin
filaments became much shorter and more disorganized,
with many cells showing reduction in F-actin at the cleav-
age furrow concomitant with accumulation of F-actin at
the poles (Figure 6B, B'; see also [9]). Similarly, after ET-
18-OCH3 treatment, F-actin accumulated at the poles,
Treatment with ML-7 causes cleavage furrow regression Figure 5
Treatment with ML-7 causes cleavage furrow regres-
sion. (A) Time-course of a dividing Drosophila spermatocyte 
treated with 80 µM ML-7 just after the time-point depicted in 
the second panel. The cell was washed with Insect Ringer's 
buffer just after the time-point depicted in the fourth panel. 
Bar, 10 µm. (B) Plot of the change in cell diameter (ordinate) 
over time (abscissa) for the Drosophila spermatocyte shown 
in A. Time-points of ML-7 addition (left arrow) and washout 
(right arrow) are indicated [see Additional file 9].
Treatment with NEM blocks cytokinesis but does not cause  cleavage furrow regression Figure 4
Treatment with NEM blocks cytokinesis but does not 
cause cleavage furrow regression. (A, B) Time-lapse 
phase-contrast images showing a dividing (A) crane-fly sper-
matocyte treated with 50 µM NEM [see Additional file 7] or 
(B) Drosophila spermatocyte treated with 10 µM NEM. In 
both experiments, cells were treated just after the time-
point depicted in the second panel. Note the appearance of 
blebs after treatment of the Drosophila spermatocyte 
(arrows) [see Additional file 8]. Bars, 10 µm. (C) Plot of the 
change in cell diameter (ordinate) over time (abscissa) for 
the crane-fly (+) and Drosophila (o) spermatocytes shown in 
A, B. NEM was added at the time-point indicated by the left 
arrow. In the crane-fly spermatocyte, cleavage remained 
arrested even after washing with Insect Ringers (right 
arrow).BMC Cell Biology 2007, 8:15 http://www.biomedcentral.com/1471-2121/8/15
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with the few actin filaments at the equator appearing
more sparsely packed than in control cells (Figure 6C, C').
After treatment with ML-7, the distribution of F-actin and
tubulin closely resembled treatment with U73122 and ET-
18-OCH3: tubulin localization was unchanged as com-
pared to control cells, whereas F-actin disappeared from
the contractile ring and accumulated at the poles. These
actin filaments were longer than in U73122-treated cells
and appeared more disorganized (Figure 6D, D'). In con-
trast, treatment with NEM had an entirely different effect:
astral microtubules were absent and F-actin in the contrac-
tile ring was dramatically reduced, with the majority of
cells (5/7) showing a compact band of F-actin at the equa-
tor. In addition, F-actin did not accumulate at the poles.
Actin filaments in the cortex were broken into small frag-
ments or completely depolymerized (Figure 6E, E').
PLC and MLCK activities are required to maintain 
activated myosin
To directly test if these inhibitors interfered with phos-
phorylation of myosin regulatory light chain (Sqh in Dro-
sophila; [30]), a known target of MLCK, we stained
dividing  Drosophila  spermatocytes for phosphorylated
Sqh (phospho-Sqh; [31]) and F-actin. In control cells,
phospho-Sqh strongly colocalized with F-actin in the con-
tractile ring, weakly colocalized with F-actin on the cell
cortex at the poles, and was found weakly colocalized with
the mitochondria and parafusorial membranes (Figure
7A). In contrast, cells treated with U73122, ET-18-OCH3
or ML-7 no longer showed evidence of phospho-Sqh or F-
actin in the contractile ring. Instead, phospho-Sqh
remained associated with the mitochondria and parafuso-
rial membranes, whereas F-actin accumulated at the poles
of the cell (Figure 7B–D).
Discussion
U73122 is widely accepted as a specific inhibitor of PLC.
Nevertheless, its mechanism of action has yet to be eluci-
dated. In some systems, NEM mimics treatment with
U73122 [32], raising the possibility that previously
reported effects of U73122 were due to alkylation of off-
target proteins rather than inhibition of PLC. To obtain
such effects with NEM, Horowitz et al. treated cells with
concentrations of NEM forty-times larger than those used
for U73122. The authors suggested that higher concentra-
tions of NEM were required because NEM lacks the
lipophilic steroid domain of U73122 that targets the NEM
moiety to membranes [32]. Consistent with their observa-
Inhibition of PLC or MLCK causes loss of phosphorylated  myosin regulatory light chain from the contractile ring Figure 7
Inhibition of PLC or MLCK causes loss of phosphor-
ylated myosin regulatory light chain from the con-
tractile ring. Phase-contrast and immunofluorescence 
images of dividing Drosophila spermatocytes stained for phos-
pho-Sqh (green), F-actin (red) and DNA (blue). (A) 
Untreated control cell. Note colocalization of phospho-Sqh 
and F-actin in the contractile ring. (B) Cell treated with 
U73122. (C) Cell treated with ET-18-OCH3. (D) Cell treated 
with ML-7. (B-C) In cells treated with these inhibitors, phos-
pho-Sqh and F-actin were no longer evident at the equator, 
whereas F-actin was relocalized to the poles. Bar, 10 µm.
F-actin relocalizes from the contractile ring to the poles upon  inhibition of PLC or MLCK Figure 6
F-actin relocalizes from the contractile ring to the 
poles upon inhibition of PLC or MLCK. Confocal images 
of dividing crane-fly spermatocytes stained for (A-E) F-actin 
and (A'-E') tyrosinated tubulin. (A, A') Untreated control cell. 
In untreated cells, F-actin was concentrated in the contractile 
ring (A) and tubulin in the spindle (A'). (B, B') Cell treated 
with U73122. (C, C') Cell treated with ET-18-OCH3. (D, D') 
Cell treated with ML-7. Cells treated with these inhibitors 
had reduced contractile ring F-actin and accumulation of F-
actin at the poles (B-D). (E, E') Cell treated with NEM. Note 
small band of F-actin at the equator, as well as reduced F-
actin density throughout the rest of the cell. Also note loss of 
astral microtubules (E'). Bar, 10 µm.BMC Cell Biology 2007, 8:15 http://www.biomedcentral.com/1471-2121/8/15
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tions, we found that the concentration required for NEM
to block cytokinesis in crane-fly spermatocytes was
twenty-times greater than the minimum effective concen-
tration of U73122. However, unlike U73122, NEM did
not cause regression of the cleavage furrow or redistribu-
tion of F-actin to the poles of the cell. In addition, the
effect of U73122 on cytokinesis was reversible in crane-fly
spermatocytes at the minimum effective concentration
[9], whereas the effect of NEM was not. In Drosophila sper-
matocytes, on the other hand, NEM stopped cleavage fur-
row ingression at a concentration well below the effective
concentration of U73122 [10], suggesting that NEM has
more pleiotropic effects. Indeed, NEM treatment resulted
in blebbing of the plasma membrane, an effect not seen
after treatment with U73122. These observations show
that the effects of U73122 are distinct from those of NEM,
and suggest that they are due to inhibition of PLC by
U73122, although our data do not rule out a mechanism
in which U73122 inhibits PLC by alkylation. Effects of
other inhibitors strengthen the argument that a PLC-
dependent pathway is involved in cytokinesis.
A second PLC inhibitor, ET-18-OCH3, had effects on cyto-
kinesis similar to U73122. ET-18-OCH3 is believed to act
by inserting into cellular membranes. Like U73122, ET-
18-OCH3 caused cleavage furrow regression and redistri-
bution of F-actin to the poles of the cell. These inhibitors
have two known overlapping cellular effects: inhibition of
PLC and release of Ca2+ from intracellular stores. In previ-
ous experiments using Drosophila  spermatocytes, we
showed that treatments predicted to greatly influence
intracellular Ca2+ levels had little effect on cytokinesis.
Treatment of cells with Ca2+ ionophores A23187 or iono-
mycin did not block cleavage, although they did induce
cell contractility and occasional ectopic cell fusion events
[10]. In contrast, chelation of intracellular Ca2+ with the
cell permeable chelator BAPTA-AM did block cytokinesis,
but only when cells were cultured in buffer lacking Ca2+
[10]. Thus, at least Drosophila spermatocytes can divide
provided they have either an intracellular or an extracellu-
lar source of Ca2+, rendering it unlikely that any effect of
ET-18-OCH3  or U73122 on intracellular Ca2+  stores
would have blocked cytokinesis in these cells. The sim-
plest explanation for the common effect of U73122 and
ET-18-O-CH3 is that PLC activity is required for cytokine-
sis.
The requirement for PLC activity in cytokinesis appears to
be conserved. Several mammalian PLC isoforms, PLCδ1,
PLCβ1 and PLCδ3, were found to localize to the cleavage
furrows of HeLa, NIH3T3 and MDCK cells during cytoki-
nesis [33,34]. Moreover, PLCγ is tyrosine phosphorylated,
and presumably activated, in dividing sea urchin embryos
[35]. U73122, which blocks cleavage in sea urchin
embryos [35], and ET-18-OCH3, which was originally
found to interfere with cytokinesis in transformed cells
and tumor cell lines [27,28], were recently found to
inhibit cytokinesis in NIH3T3 cells [34]. Although there
are currently no genetic studies showing a role for individ-
ual PLCs in cytokinesis in any system, this is likely due to
redundancy, as most organisms contain multiple PLCs.
In dividing crane-fly and Drosophila spermatocytes, two
PLC inhibitors, U73122 and ET-18-OCH3, cause cleavage
furrow regression ([9][10]; this study). Inhibition of PLC
would be expected to result in an increase in PIP2, con-
comitant with a decrease in the second messengers DAG
and IP3. PIP2 is required for cytokinesis in Drosophila sper-
matocytes and mammalian cells [10,36,37]. However, it is
unclear if an increase in PIP2 would be deleterious to the
cell. On the other hand, inhibition of the IP3 receptor with
2-APB or chelation of Ca2+ with BAPTA-AM blocked con-
tinued cleavage in Drosophila spermatocytes and zebrafish
embryos [10,38,39]. Furthermore, we previously showed
that treatment of spermatocytes with a Ca2+ ionophore
prevented the cells from responding to U73122, strongly
suggesting Ca2+  is a key downstream effector of PIP2
hydrolysis during cytokinesis [10]. Effects of the MLCK
inhibitor ML-7 confirm this interpretation.
MLCK, a potential target of Ca2+ during cytokinesis, phos-
phorylates myosin regulatory light chain on Ser-19, and to
a lesser extent on Thr-18. This diphosphorylation activates
non-muscle myosin II, allowing it to form bipolar thick
filaments postulated to constrict F-actin in the contractile
ring [40-42]. Although recent experiments have focused
on roles for other myosin activating kinases, Rho kinase
and citron kinase, in cytokinesis [43], MLCK may also
have a crucial role in this process. Indeed, treatment of
both crane-fly and Drosophila  spermatocytes with the
MLCK inhibitor ML-7 reversibly blocked cytokinesis
([29]; this study). Similarly, ML-7 interferes with cytoki-
nesis in sea urchin embryos [44] and with maintenance of
F-actin in the contractile ring in mammalian cells [45].
Strikingly, ML-7 caused cleavage furrow regression and
redistribution of actin filaments in a manner similar to
U73122 and ET-18-OCH3  (this report). Furthermore,
treatment with all three inhibitors caused loss of phos-
phorylated myosin regulatory light chain (phospho-Sqh)
from the equator of the cell. Although ML-7 is reported to
have other targets in vitro (e.g., PKA and PKC; [46]), the
most straightforward interpretation of our results is that
all three inhibitors interfere with cytokinesis by blocking
MLCK activity, myosin regulatory light chain phosphor-
ylation and myosin II contractility.
Conclusion
We showed that two different PLC inhibitors, U73122
and ET-18-OCH3, have similar effects on cleavage furrow
stability, F-actin localization and myosin regulatory lightBMC Cell Biology 2007, 8:15 http://www.biomedcentral.com/1471-2121/8/15
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chain phosphorylation, indicating a role for PLC activity
in cleavage furrow ingression. Moreover, inhibition of
MLCK with ML-7 affects cytokinesis in a similar manner,
suggesting that PIP2 hydrolysis and Ca2+ release stimulate
non-muscle myosin II to maintain actin-myosin interac-
tions and stability of the contractile ring.
Methods
Live spermatocyte preparation
Preparation of crane-fly spermatocytes in fibrin clots has
been described in detail elsewhere [47]; a modified proto-
col was used to examine Drosophila spermatocytes [10].
Briefly, testes from fourth instar crane-fly (Nephrotoma
suturalis  (Loew)) or third instar Drosophila melanogaster
were dissected in Insect Ringer's buffer (0.13 M NaCl, 5
mM KCl, 1 mM CaCl2, and 5 mM KH2PO4 and 7 mM
Na2HPO4·7H2O, pH 6.8) and transferred to a small drop
of 3–10% fibrinogen in Insect Ringer's buffer on a glass
coverslip. Testes were then pierced with an insect needle,
allowing the cells to flow out. After waiting ~30 seconds
for the cells to settle, 2–5 µl of bovine thrombin was
added to form a clot. The clot was inverted onto a drop of
Insect Ringer's buffer in a perfusion chamber and sealed
with wax or silicon grease. Cells were perfused with Insect
Ringer's buffer (with or without pharmacological agents)
throughout the experiment.
Cell treatments
All experiments were performed at room temperature
(25°C). Stock solutions of 0.01 M U73122 (1-[6-[[17 β-3-
methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-
pyrrole-2,5-dione; Calbiochem) or U73343 (1-[6-[[17 β-
3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-
pyrrolidine-dione; Calbiochem), 0.03 M ET-18-OCH3 (1-
O-Octadecyl-2-O-methyl-rac-glycero-3-phosphorylcho-
line; Biomol Research Laboratories, Inc., Plymouth Meet-
ing, PA), 0.05 M ML-7 (1-[5-Iodonaphthalene-1-
sulfonyl]-1H-hexahydro-l,4-diazepine·HCl; Sigma-
Aldrich) or 6 M NEM (Sigma-Aldrich) were prepared in
dimethylsulfoxide (DMSO) (Sigma-Aldrich) and stored at
-20°C. Prior to treatment, aliquots of each drug were
thawed and diluted to the appropriate final concentration
with Insect Ringer's buffer. To ensure that any observed
effects were not due to the solvent, control cells were
treated with the same final concentration of DMSO.
Phase-contrast and fluorescence microscopy
Live  Drosophila  spermatocytes were imaged using an
upright Zeiss Axioplan 2 microscope with a Zeiss
Apochromat 100× oil immersion objective lens (NA 1.4).
Phase-contrast and fluorescent images were recorded with
an Axiocam CCD camera using AxioVision software for
image acquisition. Live crane-fly spermatocytes were fol-
lowed using a phase-contrast inverted Nikon microscope
with a Nikon 100× oil-immersion objective (NA 1.3).
Real-time images were recorded on videotape or on DVD.
Immunostaining and fluorescence microscopy
Immunostaining and imaging of crane-fly and Drosophila
spermatocytes were performed essentially as described
[48] except that Drosophila spermatocytes were fixed with
4% paraformaldehyde (Electron Microscopy Sciences)
rather than glutaraldehyde. Drosophila spermatocytes were
stained with Alexa 488 phalloidin (Molecular Probes) for
F-actin, 4',6-diamidino-2-phenylindole (DAPI; Molecular
Probes) for DNA and 1:400 rabbit polyclonal antibody
against phospho-Ser19-Sqh (from Luke Alphey [31]) and
were mounted in Fluorescence Mounting Medium (Daxo-
cytomation). Crane-fly spermatocytes were stained using
2.2  µM Alexa 488 phalloidin for F-actin (Molecular
Probes) and 1:4000 YL1/2 rat monoclonal antibody
against tyrosinated tubulin [46] and were mounted in
Mowiol. Immunofluorescence images of Drosophila sper-
matocytes were collected with a Zeiss Axioplan 2 micro-
scope and Axiovision 4.2 software. Confocal images of
crane-fly spermatocytes were collected with Fluoview
(Olympus) software, and were processed further using
Image J (public domain software available at http://
rsb.info.nih.gov/ij/) and Adobe Photoshop. All illustra-
tions were prepared using Adobe Photoshop and were
adjusted for image presentation only (brightness, con-
trast).
Analysis of data
Cleavage furrow ingression was measured from individual
frames extracted from time-lapsed recordings using cus-
tom software and plotted using SlideWrite as described
previously [9,10].
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